Venus Remedies — 360° view

Venus Remedies, a company in the Pharmaceuticals industry, reported revenue of ₹219 crore and net profit of ₹26 crore for the September 2026 quarter.

Venus Remedies (NSE: VENUSREM-BE) closed at ₹1,236.00 on 30 Oct 2026. Its market capitalisation is ₹1,652 crore and it trades at 13.6 times earnings.

Share price
₹1,236.00 (30 Oct 2026)
Market cap
₹1,652 Cr (30 Oct 2026)
P/E
13.57 (30 Oct 2026)
Revenue
₹219 Cr (September 2026 quarter)
Net profit
₹26 Cr (September 2026 quarter)
ROCE
20.7% (FY26)
ROE
15.6% (FY26)
Book value
₹527 (FY26)
Dividend yield
0.00% (last 12 months to 30 Oct 2026)
52-week high / low
₹1,959.00 / ₹1,225.10 (30 Oct 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: VENUSREM-BE

Incorporated in 1989, Venus Remedies Ltd is a research-based pharmaceutical company focused on complex injectable formulations across critical care, oncology, anti-infectives and specialty therapies. It operates across 100+ countries, with a product basket of 195+, 1,100+ marketing authorisations and 700+ dossiers filed.{# {# https://www.bseindia.com/xml-data/corpfiling/AttachHis/29971821-bfab-4659-a9d8-7cf5dc170d02.pdf#page=36 #} #}

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.